Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMGEN FIRST YEAR EPOGEN SALES BOOST FY 1990 REVENUES 155% TO $199 MIL.

Executive Summary

Amgen Epogen sales are annualizing at over $200 mil. based on sales of the product in the three months ended March 31. The Thousand Oaks, Calif. biotech firm said its product sales, derived almost entirely from Epogen, were $53.6 mil. in the company's fourth fiscal quarter ended March 31, up from $806,000 for the same period last year. For fiscal 1990, Amgen reported product sales of $152.2 mil., up from $2.7 mil. in fiscal 1989. Although Amgen did not specifically break out Epogen sales, the company's product sales figures indicate that the erythropoietin product generated approximately $150 mil. in sales in the 10 months since its launch. Amgen revenues more than doubled in fiscal 1990 to $199 mil. Fiscal 1989 revenues of $78.1 mil. stemmed primarily from corporate partner revenues of $67.4 mil. and interest income of$7.9 mil. Epogen currently is received by an estimated 55,000 patients with anemia associated with chronic renal failure, representing "over 60% of those dialysis patients eligible for Epogen therapy," Amgen CEO Gordon Binder commented. The company reported a profit for the year of $19.1 mil.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel